본문바로가기
Language
Q
U
I
C
K

Science & Technology

SK bioscience offers total vaccine solutions thanks to the company’s efficient R&D process
and professional manufacturing process infrastructure.

Pipeline

With the paradigm shift in medical service and the spread of infectious diseases that threaten the human race,
boundless potential lies ahead for the vaccine market.

SK bioscience continues to invest in vaccine research, which will be the engine powering the life science business going forward,
and strives to secure R&D technology and broaden the product portfolio.

Domestic Vaccine Market

(Year of 2017~2028, Unit: billion $)

  • 0
  • 20
  • 40
  • 60
  • 80
  • 100
  • 120

2017

2018

2019

2020

2021

2022

2023

2024

2025

2026

2027

2028

Source: BIS Research, Global Vaccine Market - Analysis and Forecast: 2018 to 2028, 2018.11, Recreated by Biotech Policy Research Center(BPRC)

The rapidly aging population, increase in infectious diseases, and the advent of blockbuster vaccines have accelerated the growth of the global vaccine market.

The growing vaccine industry is resulting in improved profitability, new research and manufacturing technology development, and new funding opportunities.

In recent years, the development of therapeutic vaccines that can treat diseases that have already occurred (viruses, cancers, etc.) is also on the rise,
following preventive vaccines that stop infectious diseases in advance.

Vaccines are the most effective, efficient, and convenient means of preventing and treating infectious diseases,
and vaccination is emerging as an important task in public health policy. It is also becoming a global security issue due to the outbreak of transboundary epidemics.
SK bioscience’s vaccine pipeline with global competitiveness.
patent iconpatent
PIPELINE - SKYVAX, Phase Ⅰ/ Ⅱ, Phase Ⅲ, BLA, Commercial, WHO PQ
SKYVAX Phase Ⅰ/ Ⅱ Phase Ⅲ BLA Commercial WHO PQ
Launched in 2015
Approved
in 2Q 2019
Launched in 2016
Approved
in 4Q 2019
PCV
Licensed in 2016 (elderly), 2019 (infants)
Launched in 2017
Launched in 2018
Approved
in 4Q 2019
Oral Rota Pentavalent
Phase 2 study
Completed
Low Cost PVC
BILL & MELINDA GATES FOUNDATION
Phase 2 study
Completed
HPV Quadrivalent
Phase 2 study
Completed
NRRV
PATHBILL & MELINDA GATES FOUNDATION
Phase 2 study
on-going (Africa)
TCV
INTERNATIONAL VACCINE INSTITUTEBILL & MELINDA GATES FOUNDATION
submitted in 2021
PCV next generation
Sanofi Pasteur
Phase 2 study
on-going (US)
COVID-19 vaccine
보건복지부질병관리청
Phase 1 study
Completed
COVID-19 vaccine
BILL & MELINDA GATES FOUNDATIONCEPIUniversity of Washington
Phase 3
on-going